Skip to main content

Table 3 Multivariate analysis of the association between HCMV seropositivity and ESS progression during RA, study of ESPOIR cohort

From: Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients

Erosion Sharp score (baseline–1 year) score Δ > 1Odds ratioStandard errorzP > lzl[95% conf. interval]
Erosion Sharp score at baseline5.31801.93564.590.0002.605710.854
ACPA+5.19151.76354.850.0002.667710.103
HCMV0.52550.1505− 2.250.0250.29980.9213
Cumulated dose of glucocorticoids0.99970.0001− 2.290.0220.99951
Use of csDMARDs1.79871.06960.990.3240.56085.7694
Use of bDMARDs1.32980.98290.390.7000.31235.6619
\